TRANS-INT
New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier
| Coordinatore | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
Organization address
address: "PAZO DE SAN XEROME, PRAZA DO OBRADOIRO S/N" contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Sito del progetto | http://www.trans-int.eu |
| Totale costo | 10˙762˙810 € |
| EC contributo | 8˙000˙000 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2011-LARGE-5 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-05-01 - 2017-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
Organization address
address: "PAZO DE SAN XEROME, PRAZA DO OBRADOIRO S/N" contact info |
ES (SANTIAGO DE COMPOSTELA) | coordinator | 1˙878˙078.00 |
| 2 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 699˙576.00 |
| 3 |
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
Organization address
address: Pierre Brossolette 1 contact info |
FR (Chilly Mazarin) | participant | 616˙154.00 |
| 4 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address
address: BELFIELD contact info |
IE (DUBLIN) | participant | 587˙800.00 |
| 5 |
UNIVERSITE D'ANGERS
Organization address
address: Rue de Rennes 40 contact info |
FR (ANGERS) | participant | 528˙598.00 |
| 6 |
UNIVERSITE CATHOLIQUE DE LOUVAIN
Organization address
address: Place De L'Universite 1 contact info |
BE (LOUVAIN LA NEUVE) | participant | 506˙920.00 |
| 7 |
UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK
Organization address
address: Western Road contact info |
IE (CORK) | participant | 459˙100.00 |
| 8 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 434˙880.00 |
| 9 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 391˙300.00 |
| 10 |
SIGMOID PHARMA LIMITED
Organization address
address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY contact info |
IE (DUBLIN) | participant | 390˙900.00 |
| 11 |
SEROSCIENCE KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG
Organization address
address: LORANT UTCA 10 B EP FSZT 2 contact info |
HU (BUDAPEST) | participant | 346˙320.00 |
| 12 |
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Organization address
address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA contact info |
ES (BARCELONA) | participant | 302˙040.00 |
| 13 |
ISTITUTO ONCOLOGICO VENETO
Organization address
address: VIA GATTAMELAYA 64 contact info |
IT (PADOVA) | participant | 301˙400.00 |
| 14 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 296˙894.00 |
| 15 |
VENETO NANOTECH SCPA
Organization address
address: VIA SAN CRISPINO 106 contact info |
IT (PADOVA) | participant | 260˙040.00 |
| 16 |
ADVANCELL ADVANCED IN VITRO CELL TECHNOLOGIES S.A
Organization address
address: CALLE BALDARI I REIXACH 10 contact info |
ES (Barcelona) | participant | 0.00 |
| 17 |
F. HOFFMANN-LA ROCHE AG
Organization address
address: GRENZACHERSTRASSE 124 contact info |
CH (BASEL) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improvement of classical therapies and it would also make a high number of new therapies feasible. To make this happen, the final objective of Trans-INT is to design nanocarriers specifically adapted to deal with the gastrointestinal ecosystem and use them for the development of new oral nanomedicines for diseases with high socioeconomic impact (i.e. metabolic diseases, pain medication).
The concept behind TRANS-INT is the rational design of oral nanomedicines based on safety, mechanistic, bioengineering (multifunctional nanocarriers: high payload, drug protection, efficient drug transport, controlled release) and pharmaceutical technology criteria (scalable technology and stability). The project will start with nanocarrier platforms on which the partners have IPR and freedom to operate: nanocapsules, nanoparticles, micelles made of combinations of lipids, polypeptides and polysaccharides, continue with the optimization and redefinition of selected nanocarriers. It is expected to end with (i) at least one oral nanocarrier prototype with a comprehensive GLP-tox package, which could be applied for the delivery of a high number of peptide molecules, (ii) at least one nanomedicine fulfilling target product profile criteria, with a comprehensive preclinical evaluation package, (iii) substantial integrative knowledge on the feasibility and potential of oral nanocarriers and nanopharmaceuticals. TRANS-INT is expected to have a great impact no only from the new therapies/patients perspective but also from the innovation and EU industrial development perspective.'